Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

10.05.2018

FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis

10.03.2018

Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

09.25.2018

PellePharm to Present at Cantor Fitzgerald Global Healthcare Conference

09.25.2018

Eidos Therapeutics Presents Data from its Phase 1 Clinical Trial of AG10 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America

09.17.2018

Eidos Therapeutics Announces Publication of AG10 Molecular Design in Journal of Medicinal Chemistry

08.23.2018

PellePharm Shares Seminal Data Published in JCI Insight Identifying Clinical Marker for Inherited Cancer Susceptibility

08.17.2018

QED Tx – A New Company Working on a Treatment for Achondroplasia

08.15.2018

Eidos Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

08.07.2018

Eidos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

06.22.2018

Eidos Therapeutics Announces Pricing of Initial Public Offering

06.20.2018

NeuroVive Out-Licenses Targeted LHON Therapy to BridgeBio Pharma’s New Subsidiary Fortify Therapeutics

06.18.2018

BridgeBio Pharma launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

06.13.2018

PellePharm to Participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit

06.13.2018

BridgeBio Pharma Enters into Agreement to Acquire Late Stage Therapy for Ultra-Rare Disorder from Alexion; Launches Origin Biosciences to Develop and Commercialize Therapy

06.11.2018

PellePharm to Present at the 2018 UBS Global Healthcare Conference

05.21.2018

PellePharm to Present Topical Patidegib and Skin Cancer Epidemiological Data at the 7th International Investigative Dermatology Meeting

05.16.2018

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

05.03.2018

Eidos Therapeutics Completes $64M Series B Financing

04.05.2018

Eidos Therapeutics to Host Symposium on TTR Stabilization at the 16th International Symposium on Amyloidosis

03.20.2018

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn to keep up with all the latest news.

Links to an external site